
Opinion|Videos|July 12, 2024
Impact of Emerging Therapies on Outcomes for EGFR-Mutated NSCLC
Alan Chin, PharmD, BCOP, examines the PALOMA-3 trial's influence on the treatment of EGFR-mutated metastatic NSCLC and explores the evolving role of antibody-drug conjugates (ADCs) in the therapeutic landscape of EGFR-mutated NSCLC.
Advertisement
Episodes in this series

- How might the advent of subcutaneous amivantamab, currently being studied in the
PALOMA-3 trial, impact the treatment of EGFR-mutated metastatic NSCLC? What opportunities or challenges might this impose? - How do you see the role of antibody-drug conjugates (ADCs) evolving in the treatment landscape of EGFR-mutated NSCLC, and are there any in the pipeline that you are particularly excited about?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
3
Strengthening Neurology Care Through Clinical Pharmacy Integration and Collaborative Practice
4
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
5


























